The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Described herein are methods of producing prebiotic compositions that are made up of oligosaccharide compositions, as well as methods of using such prebiotic compositions in nutritional compositions and methods of producing such oligosaccharide and nutritional compositions.

The invention provides a bacterial composition which comprises from 10.sup.4 to 10.sup.12 cfu/g of Pediococcus pentosaceus cells which have the ability to induce the production of interleukin-10 to reduce inflammation in the intestinal tract among other features. Thus, the bacterial composition is useful in the amelioration of excessive crying in infants. Particularly, Pediococcus pentosaceus cells are from the strain deposited as CECT 8330. The bacterial composition can be in the form of a food supplement, a medicament, an infant formula, an edible product and a food product. Particularly, the composition is in the form of an infant food supplement in the form of oily suspension.

The present invention provides a component having effects in vivo of improving or optimizing the intestinal environment, suppressing intestinal putrefaction, or suppressing alternation of intestinal bacterial growth and/or pathological changes of intestinal bacterial growth in gut microbiota. The invention also provides an active ingredient suitably used for treating intestinal diseases. The invention provides a monoclonal IgA antibody that binds to amino acids 11 to 333 of serine hydroxymethyltransferase.

The present invention relates to a new pyrrole sulfonyl derivative, and a preparation method and medical use thereof. In particular, the present invention relates to a pyrrole sulfonyl derivative as represented by general formula (I), a preparation method thereof, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as a gastric acid secretion inhibitor and as potassium-competitive acid blockers (P-CABs), wherein each substituent group of general formula (I) is the same as that defined in the description.

The invention is directed to novel probiotic bacterial strains that colonize animal tissues, and in particular the gastrointestinal (GI) tract of aquatic animals grown in aquaculture environments and may further be engineered to express and deliver interfering RNA molecules configured to downregulate expression of one or more pathogen, or endogenous host genes.

Prebiotic composition including grape ferment, a first component, and a second component is provided. The first component is lactitol or xylooligosaccharide, and the second component is fructooligosaccharide, xylooligosaccharide, or inulin. The first component is different from the second component, and a weight ratio of the grape ferment, the first component and the second component falls within the range of 1-2:1-2:1-2. Based on this, the prebiotic composition prepared by grape ferment can be used to promote intestinal health of a subject in need thereof and enhance antioxidation in the subject.

Prebiotic composition including grape ferment, a first component, and a second component is provided. The first component is lactitol or xylooligosaccharide, and the second component is fructooligosaccharide, xylooligosaccharide, or inulin. The first component is different from the second component, and a weight ratio of the grape ferment, the first component and the second component falls within the range of 1-2:1-2:1-2. Based on this, the prebiotic composition prepared by grape ferment can be used to promote intestinal health of a subject in need thereof and enhance antioxidation in the subject.

Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.